Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide

Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide

Nupur Greene,1 Keiko Higuchi,1 Katalin Bognar,2 Eunice Chang,2 Michael S Broder2 1Neurology & Immunology (N&I), Sanofi, Cambridge, MA, USA; 2Real World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA, USACorrespondence: Nupur Greene, Global HEVA Business Partner,...

Full description

Bibliographic Details
Main Authors:	Greene N, Higuchi K, Bognar K, Chang E, Broder MS
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-12-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	administrative claims analysis disease modifying therapies medication compliance percent of days covered
Online Access:	https://www.dovepress.com/medication-adherence-and-healthcare-utilization-in-relapsing-remitting-peer-reviewed-fulltext-article-CEOR

Similar Items

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
by: Bayas A, et al.
Published: (2015-02-01)

Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients
by: Freeman L, et al.
Published: (2021-01-01)

Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
by: Boris A. Kallmann, et al.
Published: (2021-05-01)

Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis
by: N. Y. Lasch
Published: (2015-12-01)

An upper and lower bound of the Medication Possession Ratio
by: Sperber CM, et al.
Published: (2017-08-01)

Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study
by: M.L. Martínez-Ginés, et al.
Published: (2023-10-01)

Real-world data on the effectiveness and safety of teriflunomide in patients with relapsing–remitting multiple sclerosis: The EFFECT study
by: Mª.C. Durán Herrera, et al.
Published: (2022-07-01)

Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
by: Chow W, et al.
Published: (2020-11-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
by: Radu Tanasescu, et al.
Published: (2014-04-01)

Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria
by: Michael Guger, et al.
Published: (2022-06-01)

Teriflunomide in patients with multiple sclerosis
by: N. Y. Lasch, et al.
Published: (2015-12-01)

Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States
by: David M. Kern, et al.
Published: (2020-08-01)

Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data
by: Steve Vucic, et al.
Published: (2022-08-01)

Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function
by: Christopher M Blanchette, et al.
Published: (2015-02-01)

TERIFLUNOMIDE - A NEW TABLETED DRUG FOR THERAPY OF REMITTING DISSEMINATED SCLEROSIS (REVIEW)
by: E. V. POPOVA, et al.
Published: (2016-12-01)

Pengaruh Luas Penutupan Terumbu Karang Pada Lokasi Biorock dan Reef Seen Terhadap Keragaman Spesies Ikan di Wilayah Perairan Pemuteran, Bali <br><i>[Closure Area Effect On Reefs Rehabilitation in Biorock and Reef Seen Habitat Against Fish Species Diversity In Regional Aquatic Pemuteran, Bali ]<i>
by: A. Shofy Mubarak, et al.
Published: (2011-11-01)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
by: Carlo Tornatore, et al.
Published: (2022-02-01)

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
by: José E. Meca-Lallana, et al.
Published: (2023-10-01)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
by: Emanuele D’Amico, et al.
Published: (2018-09-01)

Delta T, a Useful Indicator for Pharmacy Dispensing Data to Monitor Medication Adherence
by: Pascal C. Baumgartner, et al.
Published: (2022-01-01)

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
by: Giancarlo Comi, et al.
Published: (2020-10-01)

Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
by: Virender Bhan, et al.
Published: (2023-08-01)

Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database
by: Husni ME, et al.
Published: (2022-06-01)

Utilizing Branched-chain Amino Acids for Increasing Shoot Density and Establishment Rate in Creeping Bentgrass
by: Isaac T. Mertz, et al.
Published: (2019-12-01)

Optimum Planting Date and Seed Amount of Spring Rapeseed in Saline and Marginal Lands around Urmia lake
by: Bahman Pasban Eslam
Published: (2020-10-01)

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
by: Lu X, et al.
Published: (2023-08-01)

Effect of Different Plant Extracts on Termite Species (Heterotermis indicola)
by: Nazeer Ahmed, et al.
Published: (2016-06-01)

[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]
by: Gianluca Furneri, et al.
Published: (2016-06-01)

Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis
by: Masoud Ghiasian, et al.
Published: (2024-02-01)

Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States
by: Araujo L, et al.
Published: (2023-05-01)

Does the type of disease-modifying drugs impact on the quality of life in patients with relapsing-remitting multiple sclerosis?
by: Amirreza Naseri, et al.
Published: (2020-09-01)

Fear, fight, familiarize: the experiences of people living with relapsing-remitting multiple sclerosis and taking oral medication
by: Eva Van Reenen, et al.
Published: (2019-01-01)

Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
by: Iciar Martínez-López, et al.
Published: (2020-04-01)

Analysis of a Community Pharmacy Intervention to Improve Low Adherence Rates to Oral Diabetes Medications
by: Jerica Singleton, et al.
Published: (2017-10-01)

A Cross-Sectional Audit of Nutrition and Health Claims on Dairy Yoghurts in Supermarkets of the Illawarra Region of New South Wales, Australia
by: Sam-Reith S. Wadhwa, et al.
Published: (2021-05-01)

Interferons in relapsing remitting multiple sclerosis.
by: Goodin, D
Published: (2003)

Natalizumab for relapsing-remitting multiple sclerosis
by: A. Horga, et al.
Published: (2011-01-01)

Medical image of the week: Medical administrative growth
by: Robbins RA, et al.
Published: (2018-07-01)

Patients monitoring during treatment with Teriflunomide (ORP-41)
by: Nahid Hoseini Nejad Mir
Published: (2023-01-01)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
by: Daniel Kantor, et al.
Published: (2023-03-01)